Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30;2(4):e000208. doi: 10.1161/JAHA.113.000208.
Wilburn J, Crawford SR, McKenna SP, Twiss J, Ben-L'amri M, Kemp K, Campbell S. Assessing patient reported outcome in Crohn's disease. Poster presented at the 2012 Digestive Disorders Federation Meeting; June 2012. Liverpool. [abstract] Gut. 2012; 61(Suppl 2):391. doi: 10.1136/gutjnl-2012-302514d.229
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Vakil N, McSorley DJ. Reflux symptoms after h. pylori treatment in duodenal ulcer. Poster presented at the British Society of Gastroenterology Diamond Jubilee Meeting; March 1997. [abstract] Gut. 1997 Jan; 40(Suppl 1):A128.
Brullet E, Campo R, Calvet X, Coroleu D, Rivero E, Simó Deu J. Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut. 1996 Aug;39(2):155-8. doi: 10.1136/gut.39.2.155